Senior Director, Investor Relations. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. communications@theratech. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. Who is Theratechnologies. We also use them to share usage. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. L. We also use them to share usage information with our partners. R. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30,. com uses cookies on this site. TH | September 5, 2023. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. GlobeNewswire. Stockhouse. 1-438. Find more information. MONTREAL, Nov. ( THTX 3. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. Stockhouse. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. TH 48% v4,15M c1. VANCOUVER, British Columbia, Nov. 8 million. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Theratechnologies's earnings have been declining at an average annual rate of -35. We also use them to share usage information with our partners. Theratechnologies Appoints New Board Member. Theratechnologies last announced its earnings data on September 26th, 2023. (THTX) Stock Price, Quote & News - Stock Analysis -20. $44. 4% annually. 1300 (+9. Heures de négociation. The webinar will also address system-level barriers and present real-world. 1-514-336-7800. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. Stockhouse. Patient assistance: 833-238-4372. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. - Q3 2022 North American Revenue Growth of 19%. licensed the product from TaiMed Biologics, Inc. By continuing to use our service, you agree to our use of cookies. October 13, 2022 07:30 ET | Source: Theratechnologies. THTX earnings call for the period ending February 29, 2020. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. We changed the address of the Stockhouse website from to stockhouse. Stockhouse. We currently market prescription products for people with HIV in the United States. Image source: The Motley Fool. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. - On track to meet FY2022. (NASDAQ:NASDAQ:THTX) Q1 2022 Earnings Conference Call April 13, 2022 8:30 AM ETCompany ParticipantsPaul Levesque - President & CEOPhilippe Dubuc - SVP &. Stockhouse. Montréal, Québec, Canada . 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. Find the latest Theratechnologies Inc. Register for your free account today at data. MONTREAL, Oct. 9%, while the Biotechs industry saw earnings growing at 17. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. Company Participants. - Cash, bonds and money market funds of US$22. com. (“Theratechnologies”) with the Securities and Exchange Commission (the. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. During the last trading day the stock fluctuated 12. Clinical-stage pharmaceutical company Theralase Technologies Inc. 0. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. We also use them to share usage. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. MONTREAL, Jan. We also use them to share usage. com. MONTREAL, Aug. com uses cookies on this site. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. MONTREAL, Oct. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. com uses cookies on this site. T. com uses cookies on this site. Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of. A high-level overview of Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. THTX | Complete Theratechnologies Inc. The Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. 02%. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. T. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. com. Further. Cookies are used to offer you a better browsing experience and to analyze our traffic. Denis Boucher. Theratechnologies Announces 1-for-4 Reverse Stock Split. Following the release, Knight will hold a conference call and audio webcast. com. We also use them to share usage information with our partners. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 38. Cookies are used to offer you a better browsing experience and to analyze our traffic. Trogarzo® and. . TH | February 28, 2023. com. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. TH | October 13, 2022 - Q3 2022 Consolidated. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. Cookies are used to offer you a better browsing experience and to analyze our traffic. NCU. com uses cookies on this site. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. MONTREAL, Feb. stock news by MarketWatch. Investor inquiries: Elif McDonald. When this page refreshes you will be logged in with the new address. 33 +0. (TH. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. MONTREAL, Oct. 2. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. T. 72%. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . La Bourse de Toronto a perdu. com uses cookies on this site. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. com uses cookies on this site. Theratechnologies Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Theratechnologies Inc. (Theratechnologies, or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal year 2022. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. THERATECHNOLOGIES INC. We also use them to share usage. TH | May 19, 2023. 17% from a day low at $1. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. By continuing to use our service, you agree to our use of cookies. Stockhouse. See a list of the most recent Stock Forum posts on Stockhouse. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. S. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . 31K. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. Cookies are used to offer you a better browsing experience and to analyze our traffic. 05M. Theratechnologies, Inc. By continuing to use our service, you agree to our use of cookies. com. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. View Company Info for Free. 68 to a day high of $1. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. 39 50-Day Range $0. FY2023 revenue guidance range set between $90 million and $95 million. . Conjugating the short peptide with various anti-cancer agents allows for. Senior Director, Investor Relations. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. (THTX) NasdaqCM - NasdaqCM Real Time Price. 08). We also use them to share. Forecast to breakeven in 2024 Jul 15. B2Gold Declares Fourth Quarter 2023 Dividend. - Cash, bonds and money market funds of US$22. Competitors: Unknown. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. com uses cookies on this site. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. View real-time stock prices and stock quotes for a full financial overview. com uses cookies on this site. We also use them to share usage information with our partners. D. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. 89 52. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. Thank you. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. com uses cookies on this site. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. (Image via Theralase Technologies Inc. Theratechnologies is pepped up on peptides. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. org. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. View real-time stock prices and stock quotes for a full financial overview. Cookies are used to offer you a better browsing experience and to analyze our traffic. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. TH | October 13, 2022. Register for your free account today at data. 9 million and US$19. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or. Theratechnologies inc. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. 00 to $36. Stockhouse. Stockhouse. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. 00, suggesting a possible upside of. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. View real-time stock prices and stock quotes for a full financial overview. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. It is the Company’s proprietary. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. 51 S1. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. MONTREAL, Nov. The abstract and poster can be found on Theratechnologies’ website. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. European Headquarters. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. OTCQX – this is the premium tier of OTC stocks. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Cookies are used to offer you a better browsing experience and to. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. com uses cookies on this site. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. T. Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. S. . Currency in USD Follow 2W 10W 9M 1. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Elif McDonald - Senior Director, Investor Relations. 74M. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. MONTREAL, Feb. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. According to 3 analysts, the average rating for THTX stock is "Buy. By continuing to use our service, you agree to our use of cookies. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. 81 million for the quarter. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. m. Theratechnologies inc. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. During the last trading day the stock fluctuated 4. Unveiling Silvercorp's golden potential at the Ying Mining District. T. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. Theratechnologies Stock Price, News and Company Updates. MONTREAL, Dec. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. 25. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. FAQ – Utilisateurs de TMX Argent NOUVEAU. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Katana shareholders will. Christian Marsolais, Ph. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Q3 2023 consolidated revenue of $20. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. Apr 14, 2020, 8:30 a. . It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. Investor Relations. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. Company Type For Profit. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. com uses cookies on this site. stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 81 million for the quarter. 4. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. The company reported ($0. Theratechnologies . (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. MONTREAL, Nov. Stockhouse. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. Theratechnologies Inc. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. ("Theratechnologies" or the "Company"). MONTREAL, Sept. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. T. Stockhouse. 75%. (TH. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. T. ET. Theratechnologies (THTX) Stock Price, News & Analysis $1. com uses cookies on this site. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. 2% for this period. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. Cookies are used to offer you a better browsing experience and to analyze our traffic. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. “This is yet another major achievement for our oncology program. Cookies are used to offer you a better browsing experience and to analyze our traffic. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. A live webcast of Dr. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. C. Share your ideas and get valuable. We also use them to share usage. 69 to $1. -based clinical sites participating in the conduct of the Phase. MONTREAL, Dec. MONTREAL, Aug. 20% from a day low at $1. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday.